Peceleganan antimicrobial spray shows great results!

Peceleganan spray is a topical antimicrobial agent for skin wound infections. This study published in ‘JAMA Network’ compared its safety and efficacy with Silver sulfadiazine.

A multicenter, open-label, phase 3 randomized clinical trial involving 570 patients was conducted by Yating Wei and colleagues assessing the efficacy of Peceleganan spray versus Silver sulfadiazine. Patients were randomly assigned in a 2:1 ratio to receive either 2% Peceleganan spray (number of patients=381) or 1% Silver sulfadiazine cream (SSD) (number of patients=189).

Overall, 558 patients completed the trial. After 8 days of therapy, Peceleganan demonstrated higher clinical efficacy than SSD, but with lower bacterial clearance. Adverse event rates were similar for both treatments. After 5 days, Peceleganan also showed better clinical efficacy compared to SSD, although bacterial clearance was lower.

Topical application of Peceleganan as the spray is effective and safe for treating wound infections, including those caused by drug-resistant bacteria. Future studies are required to confirm these findings and explore the mechanism of action, as concluded.